Explainer
Evidence-led entry points for non-clinicians. What is a GLP-1 receptor agonist, what does ATC A10BX mean, why are some peptides legal in Russia but not the EU.
Tirzepatide and visceral fat in Japan
A SURMOUNT J analysis links tirzepatide related weight loss with lower visceral fat and changing metabolic markers in Japan.
How GLP-1 Drugs Change What You Eat
A new narrative review details how semaglutide and tirzepatide reshape appetite, food choice, and nutrient intake, not just meal size.
The Real Risks of Grey-Market Peptides
Unapproved injectable peptides like TB-500, sold online with no prescription, carry contamination, dosing, and safety risks the FDA is still reviewing.
MASLD Screening Without a Liver Biopsy
A new review explains how FIB-4 screens for MASLD and MASH in primary care, now that semaglutide and resmetirom can treat confirmed cases.
What Patients Want in an Obesity Drug
A US survey of 800 adults finds route of administration and weight-loss efficacy outweigh simpler dosing rules when picking an obesity medication.
Ozempic Face: What the Research Says
Researchers reviewed 23 resources on GLP-1 drugs and facial volume loss. A peer response says the evidence for a distinct semaglutide effect is weak.
Semaglutide and Bipolar Disorder: The Data
A Swedish national cohort links semaglutide, not other GLP-1 drugs, to fewer bipolar hospitalizations. Here is what the data shows and does not yet show.
Why semaglutide alone beat the CRV431 combo
In a mouse model of advanced liver disease, semaglutide alone reduced tumor burden more than adding the investigational compound CRV431.
Tirzepatide, Dulaglutide: Patient Voices
Exit interviews from the SURPASS-CVOT trial capture what patients on tirzepatide and dulaglutide said helped, and what did not.
Tesamorelin under 1mg: what the data says
Egrifta's labeled tesamorelin dose is 1.28 mg daily, and no trial has published data below 1 mg or tested it against sermorelin.
Tirzepatide and eyelid styes: what's known
A two-patient case series reports recurring eyelid styes and chalazia after tirzepatide, with one positive rechallenge.
Semaglutide vs SGLT2is in Kidney Disease
A new network meta-analysis compares semaglutide, SGLT2 inhibitors and finerenone on heart and kidney outcomes in diabetic kidney disease.